References

• 2003The price of innovation: new estimates of drug development costs4,264 cited
• 1997Capital-Market Imperfections and Investment2,600 cited
• 2006Estimating The Cost Of New Drug Development: Is It Really $802 Million?906 cited
• 2001Adverse Events Associated With Prescription Drug Cost-Sharing Among Poor and Elderly Persons873 cited
• 2001Technological Innovation in the Pharmaceutical Industry: The Use of Organizational Control in Managing Research and Development861 cited
• 2004Use of Cost-Effectiveness Analysis in Health-Care Resource Allocation Decision-Making: How Are Cost-Effectiveness Thresholds Expected to Emerge?790 cited
• 1994Perspectives on PPP and Long-Run Real Exchange Rates742 cited
• 1992Brand Loyalty, Entry, and Price Competition in Pharmaceuticals after the 1984 Drug Act574 cited
• 2004Key factors in the rising cost of new drug discovery and development499 cited
• 2011THE WORLD MEDICINES SITUATION 2011427 cited
• 1991Patent Expiration, Entry, and Competition in the U.S. Pharmaceutical Industry399 cited
• 2004Market integration and convergence to the Law of One Price: evidence from the European car market391 cited
• 2004The impact of price regulation on the launch delay of new drugs—evidence from twenty‐five major markets in the 1990s344 cited
• 2007Pharmaceutical Price Controls and Entry Strategies